Skip to main content Help with accessibility Skip to main navigation

Relugolix for hormone-sensitive prostate cancer (NICE TA995)

CCG Approval Status:

Ha
Kn
Li
SF
SS
SH
Wa
WL
Wi
Date Added: 23 - Oct - 2024
Body System:
Amber retained
Relugolix for hormone-sensitive prostate cancer (NICE TA995)

The Cheshire and Merseyside Area Prescribing Group recommend relugolix for hormone-sensitive prostate cancer, in accordance with NICE TA995.

NHS Cheshire and Merseyside APPROVED